Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,995,215 papers from all fields of science
Search
Sign In
Create Free Account
SGN 40
Known as:
SGN-14
, SGN40 cpd
, Monoclonal Antibody SGN-14
Expand
A humanized monoclonal antibody targeting the CD40 antigen with potential antineoplastic activity. CD-40, an integral membrane protein found on the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
NCIt Antineoplastic Agent Terminology
antigen binding
Broader (1)
dacetuzumab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
[Research advances of anti-CD40 monoclonal antibody].
Longlong Luo
,
Yan Zhang
,
C. Hou
,
C. Qiao
,
Yan Li
Zhongguo shi yan xue ye xue za zhi
2013
Corpus ID: 36184985
CD40 and its receptor CD40L are a very important pair of co-stimulating molecule in immune response, which have extensive…
Expand
2011
2011
Cancer Therapy : Preclinical Distinct Apoptotic Signaling Characteristics of the Anti-CD 40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma
T. Lewis
,
R. Mccormick
,
+5 authors
C. Law
2011
Corpus ID: 40712406
Purpose: Individually targeting B-cell antigens with monoclonal antibody therapeutics has improved the treatment of non-Hodgkin…
Expand
2010
2010
Langerhans Cells Do Not Produce Interferon-c
2010
Corpus ID: 189859673
Interferon-g (IFN-g) is the predominant cytokine during Th1dominated immune reactions, participates importantly during antigen…
Expand
2010
2010
A Fully Novel Human Anti-CD40 Monoclonal Antibody, 4D11 (ASKP1240), Renders Allo-Antigen Stimulated CD4+T Cells To Acquire Immuno-Regulatory Function
G. Hirokata
,
K. Yamashita
,
+8 authors
S. Todo
2010
Corpus ID: 80423046
2009
2009
Abstract #LB-138: A gene signature predicts sensitivity to the partial CD40 agonist, dacetuzumab (SGN-40), in patients with diffuse large B-cell lymphoma
B. Burington
,
R. Advani
,
+10 authors
D. Dornan
2009
Corpus ID: 90383088
Background: Agonism of the CD40 pathway represents a unique therapeutic opportunity for the treatment of diffuse large B-cell…
Expand
2008
2008
Chapter 2 Prevention of kidney allograft rejection using anti-CD 40 and anti-CD 86 in primates
K. Haanstra
,
J. Ringers
,
+4 authors
M. Jonker
2008
Corpus ID: 25577694
Background Costimulation blockade has been proposed to induce allograft tolerance. We combined an antagonist anti-CD40 monoclonal…
Expand
2005
2005
Phase I trial of a humanized anti-CD40 monoclonal antibody (SGN-40) in the treatment of multiple myeloma
M. Hussein
,
J. Berenson
,
+7 authors
M. Mcdonald
2005
Corpus ID: 68891585
6581 Background: CD40 is a member of the Tumor Necrosis Factor (TNF) family of receptors and is expressed on the surface of B…
Expand
2004
2004
Cells : Clinical Implications Antibody , Induces Cytotoxicity in Human Multiple Myeloma Mechanisms by which SGN-40 , a Humanized Anti-CD 40
Y. Tai
,
L. Catley
,
+11 authors
K. Anderson
2004
Corpus ID: 14289946
CD40 is expressed on B-cell malignancies, including human multiple myeloma (MM) and a variety of carcinomas. We examined the…
Expand
2003
2003
Anti-CD 40 monoclonal antibody therapy in combination with irradiation results in a CD 8 T-cell – dependent immunity to B-cell lymphoma
J. Honeychurch
,
M. Glennie
,
Peter W M Johnson
,
T. Illidge
2003
Corpus ID: 1751155
The mechanisms of interaction between anti-CD40 monoclonal antibody (mAb) therapy and external beam irradiation were investigated…
Expand
2003
2003
CD 40 induces human multiple myeloma cell migration via phosphatidylinositol 3 – kinase / AKT / NF-B signaling
Y. Tai
,
K. Podar
,
+9 authors
K. Anderson
2003
Corpus ID: 8366053
Multiple myeloma (MM) is characterized by clonal expansion of malignant plasma cells in the bone marrow and their egress into…
Expand